Novartis Vaccine Bexsero Sees High Uptake in First Large-Scale Public Vaccination Programme
Novartis has announced the initial results of a large-scale vaccination campaign with Bexsero (Meningococcal Group B Vaccine [rDNA, component, adsorbed]) to help protect against meningitis B within the Saguenay-Lac-Saint-Jean region of Québec, Canada. This public programme adds to the growing real-world experience of Bexsero, which is approved in 34 countries, including the EU, Australia and Canada.
This regional programme is the first of its kind globally and has reached 81% of the campaign's target population within the first 3 months. This encompasses more than 45,000 infants, young children and adolescents from 2 months to 20 years of age. The high rate of uptake in this public vaccination programme with Bexsero demonstrates the value placed on preventing meningitis B within communities that are afforded access.
"A high level of uptake through a public vaccination programme is critical to achieving community-wide protection against a devastating and unpredictable disease like meningitis B," said Andrin Oswald, Division Head, Novartis Vaccines. "Thanks to the decisive leadership and urgency with which the public health officials in Québec have acted, lives will likely be saved. We are committed to continuing to work with health authorities globally to ensure public access to Bexsero."
Ninety-four percent of Québec's invasive meningococcal disease cases in those aged 1–24 years old were caused by meningitis B between 2009 and 2011. In the past few years, the number of people infected with meningitis B has been higher in the Saguenay-Lac-Saint-Jean region than in other Québec regions, relative to the population. The decision to implement this vaccination campaign in the region was based on experts' recommendations, following Bexsero's approval in Canada in December 2013 for use in individuals from 2 months to 17 years of age. Second doses of Bexsero will be available in the fall of this year and the programme will conclude on 31 December 2014.
Bexsero is the first broad coverage vaccine to help protect against meningitis B. Since its launch in 2013, over half a million doses have been shipped worldwide]. Bexsero was also recently provided in the US to students at Princeton University and the University of California, Santa Barbara (UCSB) under a treatment Investigational New Drug (IND) designation from FDA in response to local meningitis B outbreaks on both campuses. In June 2014, Novartis submitted a Biologic License Application to the FDA for US marketing approval of Bexsero, which initiated a rolling submission process, following the receipt of a Breakthrough Therapy designation in April 2014.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance